Altogether, our data indicate that RBMS1 is a promising anti‐metastasis target, and the RBMS1 inhibitor NTP is a potent therapeutic agent for anti‐metastasis therapy in human lung cancer. Here, RBMS1 is linked to lung carcinoma.